Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Acid-stable Protease Inhibitor
2. Miraclid
3. Mr 20
4. Mr 20 (magnetic Powder) Of Urinastatin
5. Mr-20 (magnetic Powder)
6. Trypsin Inhibitor Mr-20
7. Ulinastatin
8. Urinary Trypsin Inhibitor
9. Urinary Trypsin Inhibitor (68)
10. Urinary Trypsin Inhibitor-like Inhibitor (43)
11. Urinastatin
12. Uti(68)
13. Uti68
1. 80499-32-7
2. 80449-32-7
3. 3-(furan-2-yl)-2,4-dioxaspiro[5.5]undec-8-ene
4. Trypsin Inhibitor (human Urine Urinastatin Protein Moiety)
5. 3-(furan-2-yl)-2,4-dioxaspiro[5.5]undec-9-ene
6. 2,4-dioxaspiro(5.5)undec-8-ene, 3-(2-furanyl)-
7. Trypsin Inhibitor Mr-20
8. Mr-20 (magnetic Powder)
9. Uti(68)
10. Acid-stable Protease Inhibitor
11. Urinary Trypsin Inhibitor (68)
12. Mr 20
13. Unii-or3s9if86u
14. Uristatin
15. Mingin
16. Urinary Trypsin Inhibitor-like Inhibitor (43)
17. Trypsin Inhibitor Uti
18. Ulinastatin [inn:jan]
19. Trypsin Inhibitor, Mingin
20. Trypsin Inhibitor, Bikunin
21. Urinary Trypsin Inhibitor 1
22. 3-(2-furanyl)-2,4-dioxaspiro(5.5)undec-8-ene
23. Dtxsid801001247
24. Bcp08067
25. Akos025401879
26. Ac-26827
27. Hy-21646
28. D77201
29. 9-(2-furyl)-8,10-dioxaspiro[5.5]undec-3-ene
| Molecular Weight | 220.26 g/mol |
|---|---|
| Molecular Formula | C13H16O3 |
| XLogP3 | 2.1 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 220.109944368 g/mol |
| Monoisotopic Mass | 220.109944368 g/mol |
| Topological Polar Surface Area | 31.6 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 266 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Trypsin Inhibitors
Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. (See all compounds classified as Trypsin Inhibitors.)
API SUPPLIERS
Date of Issue : 2021-04-12
Valid Till : 2024-01-28
Written Confirmation Number : WC-0256
Address of the Firm :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
Date of Issue : 2021-04-12
Valid Till : 2024-01-28
Written Confirmation Number : WC-0256
Address of the Firm : N.H.8, Near Grid, Kabilpore, City Navasari-396424, Dist. Navsari, Gujarat
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]KDMF
Registrant Name : Sampoong Finechem Co., Ltd.
Registration Date : 2021-06-30
Registration Number : 20210630-210-J-1047
Manufacturer Name : BSV BioScience GmbH
Manufacturer Address : Max-Planck-Strasse 12, 52499 Baesweiler, Germany
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...
About the Company : Hanways Chempharm Co., Limited, the former one is Hubei Hanways Pharchem CO.,Limited, set up in 2009 in Wuhan, China. We are engaged in supplying APIs, pharmaceutical intermediate...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.
Lead Product(s): Urinastatin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Lead Product(s) : Urinastatin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bharat Serums to assess sepsis drug Ulinastatin for Covid-19
Details : The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
JP
Monograph in Japanese Pharmacopoeia : Ulinastati...
Package Size : 3700 Units
Price (¥) : 37,852
Storage Temprature °C : -20 to -30°C
Assay Test : A/ EA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
